Optimal duration of chemotherapy in advanced non-small cell lung cancer

Current Treatment Options in Oncology

Volumn 8, Issue 1, 2007, Pages 38-46

  Lustberg, Maryam B ^a   Edelman, Martin J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; PACLITAXEL; PEMETREXED; PLACEBO; VINBLASTINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CANCER STAGING; DRUG ADMINISTRATION; LUNG TUMOR; METABOLISM; METHODOLOGY; ONCOLOGY; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; PLATINUM; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 36048959189     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0020-6     Document Type: Review

References (30)

1. Cullen MH, Billingham LJ, Woodroffe CM, et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194
2. Anonymous: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials - Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311: 899-909.
3. Wozniak AJ, Crowley JJ, Balcerzak SP, et al (2001) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465.
4. Sandler AB, Nemunaitis J, Denham C, et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
5. D'Addario G, Pintilie M, Leighl N, Feld R, Cerny T, Shepherd FA (2005) Platinum -based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 23:2926-2936
6. American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018
7. Buccheri GF, Ferrigno D, Curcia A, et al. (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63(3):428-432
8. Pfister DG, Johnson DH, Azzoli CG, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22(2):330-353
9. Smith IE, O'Brien ME, Talbot DC, et al. (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19(5):1336-1343
10. Socinski M, Schell M, Peterman A, et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 20:1335-1343
11. von Plessen C, Bergman B, Andresen O, et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95(8):966-973
12. Edelman MJ, Clark J, Chansky K, Albain K, Gandara DR. (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer: Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/ Vinorelbine followed by Docetaxel (SWOG 9806). Clin Cancer Res 10(16):5418-5424
13. Binder D, Schweisfurth H, Grah C, et al.: Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): Results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol. 2006 Oct 10; (Epub ahead of prin).
14. DePierre A, Quiox E, Mercier M, Breton J, Moro-Sibilot D, Debeiuvre D. (2001) Maintenance chemotherapy in advanced non-small cell lung cancer: A randomized trial of vinorelbine versus observation in patients responding to induction chemotherapy. Proc Am Soc Clin Oncol 20:309a
15. Johnson DH, Fehrenbacher L, Novotny WF, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191
16. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 355:2542-2550
17. Ratain MJ, Eisen T, Stadler WM, et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512
18. Herbst RS, Prager D, Hermann R, et al (2005) TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
19. Herbst RS, Giaccone G, Schiller JH, et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794
20. Giaccone G, Herbst RS, Manegold C, et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784
21. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 22(suppl 14S):619S, 2004
22. Herbst RS, Giaccone G, Schiller J, et al (2003) Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC) [abstract 2523]. Proc Am Soc Clin Oncol 22:627
23. Paez JG, Janne PA, Lee JC, et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-14500
24. Lynch TJ, Bell DW, Sordella R, et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2139-2159
25. Tsao MS, Sakurada A, Cutz JC, et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144
26. Pérez-Soler R, Chachoua A, Hammond LA, et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
27. Fossella FV, DeVore R, Kerr R, et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18:2354-2362
28. Shepherd F, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel vs. best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2013
29. Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
30. Shepard F, Pereira J, Ciulenanu T. (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial. J Clin Oncol 2:622s